PharmTech AI Pulse Check panelists explain why attribution, audit trails, and sign-off matter more than AI watermark detection for GxP quality teams.
|Articles|October 2, 2018
USP
USP is a scientific, nonprofit organization that sets standards for quality medicines. USP standards are the industry benchmark because of the robust scientific process used in their development and our unparalleled service.
Advertisement
USP is a scientific, nonprofit organization that sets standards for quality medicines. USP standards are the industry benchmark because of the robust scientific process used in their development and our unparalleled service. We offer more than 3700 highly characterized Reference Standards, including 1600 impurity Reference Standards, most directly tied to 4900 official monographs and 350 general chapters with assays, tests, and procedures.
12601 Twinbrook Parkway, Rockville, MD 20852-1790, USA
tel. 1.301.881.0666/00.800.4875.5555 (select Europe)
custsvc@usp.org
AAPS Booth Number: 1318
Advertisement
Related to this article
Ron Scarboro, Azurity Pharmaceuticals, explains how cross-functional development, disciplined reformulation, and post-approval metrics can help proven medicines work in everyday use.
The FDA approves oral pritelivir for drug-resistant herpes sores in immunocompromised patients; what it means for antiviral development and manufacturing.
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Equivalence test using two one-sided tests are widely used for demonstrating the comparability of treatment effects in different research fields. The method described in the manuscript aims to use simulations in Microsoft Excel to compute power for 2 one-sided tests for two groups with unequal variances.
Richard Jaenisch examines whether FDA's NAM pathway truly shortens drug pipelines or just shifts the evidentiary burden elsewhere.
Susan J. Schniepp, distinguished fellow with Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical, with Parexel, clear up some of the confusion about what does and does not need to be complied with regarding standards set by international pharmacopoeias.
Advertisement
Advertisement